Group 1 - Bank of America Securities has lowered the core net profit forecasts for Hengan International (01044) by 3% and 1% for 2025 and 2026 respectively [1] - The target price has been raised by 18% to HKD 30, based on an improved industry competitive landscape and an increased target price-to-earnings ratio to 13 times [1] - Despite the lack of long-term growth drivers, the company offers a considerable dividend yield, maintaining a "Neutral" rating [1] Group 2 - The bank expects Hengan's revenue in the second half of 2025 to grow by 1% year-on-year to RMB 10.9 billion, driven by improvements across all three business segments [1] - Tissue sales are projected to increase by 5% year-on-year, accelerating from 3% growth in the first half of the year [1] - The bank anticipates that the gross margin in the second half of the year will improve to 33.1%, primarily due to better product mix and normalization of raw material costs [1] - Core net profit for the second half of 2025 is expected to grow by 8% to RMB 1 billion year-on-year [1]
美银证券：升恒安国际目标价至30港元 料去年下半年核心净利润升8%